Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Thymitaq

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
BACKGROUND To evaluate the tolerability and efficacy of nolatrexed in patients with advanced hepatocellular carcinoma. PATIENTS… Expand
Is this relevant?
2003
2003
BACKGROUND Some anticancer drugs inhibit thymidylate synthase (TS), a key enzyme for thymidine nucleotide biosynthesis. Cells can… Expand
Is this relevant?
2001
2001
We report on two randomized trials performed in the USA and Europe, which compared methotrexate and nolatrexed as treatment for… Expand
Is this relevant?
2000
2000
Abstract In this study, the downstream effects of thymidylate synthase (TS) inhibition in L1210 (p53 mutant) and HL60 (p53 null… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Thymidylate synthase (TS), a critical enzyme in the de novo synthesis of thymidylate, is an important target for… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
1999
1999
Phase I studies of p.o. administered nolatrexed dihydrochloride (AG337, THYMITAQ), a nonclassical thymidylate synthase inhibitor… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
1999
1999
Summary2-Amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)-quinazoline dihydrochloride (nolatrexed dihydrochloride, Thymitaq… Expand
  • table 1
  • table 2
  • figure 2
  • figure 1
  • table 3
Is this relevant?
1998
1998
Thymidylate synthase plays an essential role in the synthesis of DNA. Recently, several new and specific thymidylate synthase… Expand
Is this relevant?
1998
1998
Human thymidylate synthase (TS) contains three highly conserved residues Ile-108, Leu-221, and Phe-225 that have been suggested… Expand
Is this relevant?
1996
1996
AG337 is a recent non-classical thymidylate synthase inhibitor with promising activity and manageable toxicity in phase I… Expand
Is this relevant?